We expect the launch of Agent DCB in Europe to help Boston Scientific improve its presence in the coronary heart disease market in the region. There is huge potential for growth in this market considering that coronary heart disease causes an estimated 1.8 million deaths every year in Europe, making it the single most common cause of death in the region.

Topics:  agent dcb   boston scientific   europe   improve   presence   coronary   market   heart   disease   region   
BING NEWS:
  • Boston Scientific Corp.
    No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
    05/22/2023 - 12:31 pm | View Link
  • Boston Scientific
    Medical device giant Boston Scientific added to its string of recent acquisitions by announcing its plan to buy Axonics, a maker of neurostimulation devices that treat urinary and bowel ...
    10/9/2012 - 8:10 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News